Neurolixis, Inc. Press releases
Aug 20, 2019
The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.
Jul 22, 2019
Neurolixis, Inc. announced the publication of scientific data demonstrating rapid and long-lasting antidepressant activity of the Company's 'biased agonist' drug candidate, NLX-101 in a robust rodent model of depression.
Mar 12, 2019
The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.
Feb 20, 2019
Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.
Feb 11, 2019
A new article in the Journal of Medicinal Chemistry describes the characterization of novel selective serotonin 5-HT1A receptor biased agonists.
Feb 22, 2016
Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease.
Nov 22, 2015
Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Steven A.
Jun 24, 2015
Neurolixis Inc. announced that it had been awarded a second research grant by the Rett Syndrome Research Trust (RSRT) to support the development of its novel serotonin 5-HT1A receptor agonist, NLX-101.
Jun 09, 2015
Neurolixis, Inc., a private biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, will present the latest preclinical data on its drug candidate, NLX-112, at the 19th International Congress of...
Jun 04, 2015
Neurolixis SAS, the French subsidiary of Neurolixis Inc., a privately held biotechnology company, announced today that it had been awarded 'Jeune Entreprise Innovante' (JEI; literally 'Young Innovative Company') status by the French Public Finances...